mbiomics, a Munich-based company founded in 2020, announced the third closing of its Series A financing round. With newly raised 12 million EUR, the total round volume reached 30 million EUR. The article states that investors include MIG Fonds and Bayern Kapital. The funding marks a transition from a pure technology platform to clinical application in humans. The lead drug candidate MBX-116 is planned to be tested in a Phase 1B study in 2027 in patients with advanced melanoma.
About Mbiomics
mbiomics is developing a microbiome cancer co-therapy.
Munich, Germany
Read Company ProfileFrequently Asked Questions
What type of funding round did Mbiomics raise?
Mbiomics raised a series-a round.
How much did Mbiomics raise in its series-a?
Mbiomics raised $30,000,000 EUR in its series-a.
When did Mbiomics raise its series-a?
Mbiomics raised its series-a on 2026-04-28.
Who invested in Mbiomics's series-a?
The investors in Mbiomics's series-a are: MIG Fonds, Bayern Kapital.
What type of investment was Mbiomics's series-a?
Mbiomics's series-a was a equity investment.
How will Mbiomics use the funds from its series-a?
Mbiomics plans to use the funds for: transition from technology platform to clinical application in humans.